Analyst Bumps Up Price Target For Avadel Pharmaceuticals After Favorable Patent Ruling
Last Friday, Delaware District Court granted Avadel Pharmaceuticals plc's (NASDAQ: AVDL) motion to delist the ‘963 Xyrem REMS patent.
Avadel Pharmaceuticals PR Confirms Favorable Ruling On Motion To Delist REMS Patent From FDA’s Orange Book
Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that the United States District Court for the District of Delaware (the
Goldman Sachs Maintains Neutral on Jazz Pharmaceuticals, Raises Price Target to $192
Goldman Sachs analyst Madhu Kumar maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Neutral and raises the price target from $170 to $192.
Needham Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $208
Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and lowers the price target from $210 to $208.
Jazz Pharmaceuticals Q3 Adj. EPS $5.17 Beats $4.66 Estimate, Sales $940.65M Beat $939.06M Estimate
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $5.17 per share which beat the analyst consensus estimate of $4.66 by 10.94 percent. This is a 23.1 percent increase over earnings of $4.20 per share from
Jazz Pharma’s Zepzelca For Lung Cancer Flunked Confirmatory Trial, But FDA Will Not Pull Accelerated Approval
A petition was filed requesting that the FDA initiate proceedings to withdraw approval of all medications containing lurbinectedin, currently marketed under the brand Zepzelca by Jazz Pharmaceuticals plc (NASDAQ: JAZZ).
Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline
SVB Leerink downgraded Zymeworks Inc (NASDAQ:ZYME) to Market Perform with a price target of $8, down from $19 following the recent divestiture of…
Jazz Obtains Exclusive Rights To Zymeworks’ Cancer Candidate In Almost $2B Biobuck Deal
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) will acquire development and commercialization rights to Zymeworks Inc’s (NASDAQ:ZYME) zanidatamab across all indications in the U.S., Europe, Japan,…
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
UBS Slashes PT On This Stock By Over 89%? Plus Evercore ISI Group Predicts $150 For First Solar
Evercore ISI Group boosted First Solar, Inc. (NASDAQ: FSLR) price target from $88 to $150. First Solar shares rose 1.7% to $138.49 in pre-market trading.